Atrás

Top Glove Corporation Bhd.

Calidad de datos: 100%

TGLVY

OTC Healthcare Medical - Instruments & Supplies

$0.48

$0.00 (0.00%)

Cap. Mercado: 954.14M

Rango del Día

$0.48 $0.52

Rango de 52 Semanas

$0.46 $0.88

Volumen

2,100

Promedio 50D / 200D

$0.56 / $0.58

Cierre Anterior

$0.48

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica	Acción	Mediana del Sector
P/E	7.2	0.4
P/B	0.2	2.9
ROE %	2.5	3.7
Net Margin %	3.8	3.9
Rev Growth 5Y %	-32.0	10.0
D/E	0.2	0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período	EPS Est.	Ingresos Est.	Analistas
FY2027	$0.00 $0.00 – $0.00	4.4 B	0
FY2026	$0.00 $0.00 – $0.00	4.1 B	0

Puntos Clave

Revenue declined -32.04% annually over 5 years

ROE of 2.50% is below average

Debt/Equity of 0.18 — conservative balance sheet

Generating 156.31M in free cash flow

P/E of 7.22 — trading at a low valuation

Revenue growth is accelerating — 1Y growth exceeds 5Y average by 70.82%

Crecimiento

Revenue Growth (5Y)

-32.04%

Revenue (1Y)38.78%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Calidad

Return on Equity

2.50%

ROIC1.19%

Net Margin3.79%

Op. Margin2.55%

Seguridad

Debt / Equity

0.18

Current Ratio2.75

Interest Coverage17.42

Valoración

P/E Ratio

7.22

P/B Ratio0.20

EV/EBITDA16.92

Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	38.78%	Revenue Growth (3Y)	24.33%
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	-32.04%	Earnings Growth (5Y)	-63.88%
Profitability
Revenue (TTM)	3.49B	Net Income (TTM)	132.18M
ROE	2.50%	ROA	2.11%
Gross Margin	2.55%	Operating Margin	2.55%
Net Margin	3.79%	Free Cash Flow (TTM)	156.31M
ROIC	1.19%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0.18	Current Ratio	2.75
Interest Coverage	17.42	Dividend Yield	0.00%
Valuation
P/E Ratio	7.22	P/B Ratio	0.20
P/S Ratio	0.27	PEG Ratio	-0.16
EV/EBITDA	16.92	Dividend Yield	0.00%
Market Cap	954.14M	Enterprise Value	1.51B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	3.49B	2.51B	2.26B	5.57B	16.36B
Net Income	132.18M	-18.27M	-878.61M	275.73M	7.76B
EPS (Diluted)	0.05	-0.03	-0.48	0.11	3.84
Gross Profit	89.01M	265.32M	64.32M	953.38M	11.10B
Operating Income	89.01M	-182.55M	-532.62M	354.87M	10.03B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	6.27B	6.96B	7.06B	8.12B	9.78B
Total Liabilities	1.49B	1.12B	1.14B	1.32B	2.56B
Shareholders' Equity	4.76B	5.81B	5.89B	6.75B	7.17B
Total Debt	849.86M	422.09M	581.85M	417.07M	482.38M
Cash & Equivalents	298.39M	282.84M	279.77M	433.44M	875.20M
Current Assets	1.45B	1.83B	1.69B	2.11B	4.35B
Current Liabilities	528.78M	949.80M	923.87M	996.49M	2.20B

Puntuaciones de Estrategias

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Cash Flow Compounder

#468 of 1024

Custom Deep Value Investing (Seth Klarman)

#456 of 820

Growth Price/Sales Ratio Focus (Ken Fisher)

#84 of 616

Value Defensive Investing (Benjamin Graham)

#93 of 708

Actividad Reciente

Entró Cash Flow Compounder

Mar 24, 2026

Entró Deep Value Investing (Seth Klarman)

Mar 24, 2026

Entró Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

Entró Defensive Investing (Benjamin Graham)

Mar 24, 2026